Loading…
Reduced serum TNF alpha level in chronic schizophrenia patients with or without tardive dyskinesia
Mounting evidences have demonstrated the association of altered immune factors with neurodevelopmental and pathological progression of schizophrenia. However, whether immune factors play any role in the pathogenesis of tardive dyskinesia (TD) has been underexplored. To our best knowledge, ours is am...
Saved in:
| Published in: | Progress in neuro-psychopharmacology & biological psychiatry 2014-10, Vol.54, p.259-264 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c389t-14869880254f555eba68d27793caadb8057aef2b8604ee38ca59107c60841a233 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c389t-14869880254f555eba68d27793caadb8057aef2b8604ee38ca59107c60841a233 |
| container_end_page | 264 |
| container_issue | |
| container_start_page | 259 |
| container_title | Progress in neuro-psychopharmacology & biological psychiatry |
| container_volume | 54 |
| creator | Tian, Li Tan, Yunlong Chen, Dachun Lv, Menghan Tan, Shuping Soares, Jair C. Zhang, Xiang Yang |
| description | Mounting evidences have demonstrated the association of altered immune factors with neurodevelopmental and pathological progression of schizophrenia. However, whether immune factors play any role in the pathogenesis of tardive dyskinesia (TD) has been underexplored. To our best knowledge, ours is among the piloting studies examining the association of TNF alpha with extrapyramidal symptoms of schizophrenic patients so far.
The aim of this study was to assess the clinical significance of serum TNF alpha level in chronic schizophrenia, especially its potential association with TD.
Serum TNF alpha level was measured in a sandwich enzyme-linked immunosorbent assay (ELISA) from 46 medicated chronic schizophrenia patients with TD, 43 chronic schizophrenia patients without TD, and 43 healthy control subjects. The symptoms of schizophrenia were assessed by the positive and negative syndrome scale (PANSS).
Chronic patients both with TD and without TD had significantly lower serum level of TNF alpha than controls (TD=9.5±2.1pg/ml, non-TD=10.7±1.8pg/ml, control=37.8±3.4pg/ml, p0.05). Serum TNF alpha level was negatively correlated with the PANSS total score in the whole schizophrenia patients (p |
| doi_str_mv | 10.1016/j.pnpbp.2014.06.012 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1554473035</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0278584614001316</els_id><sourcerecordid>1554473035</sourcerecordid><originalsourceid>FETCH-LOGICAL-c389t-14869880254f555eba68d27793caadb8057aef2b8604ee38ca59107c60841a233</originalsourceid><addsrcrecordid>eNp9kcFu1DAQhi0EokvhCZCQL0hcNowd23EOHFDVAlIFEipna-JMFC_ZJNjJovL0eLsL3DjNHL75Z_QNYy8FFAKEebsr5nFu5kKCUAWYAoR8xDbCVnarpDCP2QZk7rVV5oI9S2kHAKKE8im7kKqutbF6w5qv1K6eWp4ornt-9_mG4zD3yAc60MDDyH0fpzF4nnwffk1zH2kMyGdcAo1L4j_D0vMpPtRpXfiCsQ0H4u19-h5GSgGfsycdDolenOsl-3ZzfXf1cXv75cOnq_e3W1_aetkKZU1tLUitOq01NWhsK6uqLj1i21jQFVInG2tAEZXWo64FVN6AVQJlWV6yN6fcOU4_VkqL24fkaRhwpGlNTmitVJUF6IyWJ9THKaVInZtj2GO8dwLcUa7buQe57ijXgXFZbp56dV6wNntq_878sZmB12cAk8ehizj6kP5xtlI558i9O3GUdRwCRZd8tpnfECL5xbVT-O8hvwFrwZk7</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1554473035</pqid></control><display><type>article</type><title>Reduced serum TNF alpha level in chronic schizophrenia patients with or without tardive dyskinesia</title><source>ScienceDirect Journals</source><creator>Tian, Li ; Tan, Yunlong ; Chen, Dachun ; Lv, Menghan ; Tan, Shuping ; Soares, Jair C. ; Zhang, Xiang Yang</creator><creatorcontrib>Tian, Li ; Tan, Yunlong ; Chen, Dachun ; Lv, Menghan ; Tan, Shuping ; Soares, Jair C. ; Zhang, Xiang Yang</creatorcontrib><description>Mounting evidences have demonstrated the association of altered immune factors with neurodevelopmental and pathological progression of schizophrenia. However, whether immune factors play any role in the pathogenesis of tardive dyskinesia (TD) has been underexplored. To our best knowledge, ours is among the piloting studies examining the association of TNF alpha with extrapyramidal symptoms of schizophrenic patients so far.
The aim of this study was to assess the clinical significance of serum TNF alpha level in chronic schizophrenia, especially its potential association with TD.
Serum TNF alpha level was measured in a sandwich enzyme-linked immunosorbent assay (ELISA) from 46 medicated chronic schizophrenia patients with TD, 43 chronic schizophrenia patients without TD, and 43 healthy control subjects. The symptoms of schizophrenia were assessed by the positive and negative syndrome scale (PANSS).
Chronic patients both with TD and without TD had significantly lower serum level of TNF alpha than controls (TD=9.5±2.1pg/ml, non-TD=10.7±1.8pg/ml, control=37.8±3.4pg/ml, p<0.001). Compared to patients without TD, TD patients showed marginally significant reduction in the serum TNF alpha level (p=0.05). The reduced TNF alpha level was not significantly affected by daily dose or duration of antipsychotic drugs (p>0.05). Serum TNF alpha level was negatively correlated with the PANSS total score in the whole schizophrenia patients (p<0.01), but no significant association with TD severity was observed.
Our results suggested that at chronic stage, serum TNF activity is associated with psychopathology of schizophrenia patients, but whether it can be a biomarker for TD needs further clarification in the future.
•Chronic schizophrenia patients had lower TNFα level than healthy controls.•A marginally significant decrease in TNFα was noted in TD than non-TD patients.•TNFα was correlated with psychopathology of schizophrenia, but not TD severity.</description><identifier>ISSN: 0278-5846</identifier><identifier>EISSN: 1878-4216</identifier><identifier>DOI: 10.1016/j.pnpbp.2014.06.012</identifier><identifier>PMID: 24995685</identifier><identifier>CODEN: PNPPD7</identifier><language>eng</language><publisher>Amsterdam: Elsevier Inc</publisher><subject>Adult and adolescent clinical studies ; Antipsychotic Agents - therapeutic use ; Antipsychotics ; Biological and medical sciences ; Chronic Disease ; Cross-Sectional Studies ; Enzyme-Linked Immunosorbent Assay ; Female ; Humans ; Male ; Medical sciences ; Middle Aged ; Movement Disorders - complications ; Movement Disorders - immunology ; Nervous system (semeiology, syndromes) ; Nervous system as a whole ; Neurology ; Neuropharmacology ; Pharmacology. Drug treatments ; Psychiatric Status Rating Scales ; Psycholeptics: tranquillizer, neuroleptic ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology ; Psychopathology. Psychiatry ; Psychopharmacology ; Psychoses ; Schizophrenia ; Schizophrenia - complications ; Schizophrenia - drug therapy ; Schizophrenia - immunology ; Severity of Illness Index ; Tardive dyskinesia ; Tumor necrosis factor ; Tumor Necrosis Factor-alpha - blood</subject><ispartof>Progress in neuro-psychopharmacology & biological psychiatry, 2014-10, Vol.54, p.259-264</ispartof><rights>2014 Elsevier Inc.</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2014 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c389t-14869880254f555eba68d27793caadb8057aef2b8604ee38ca59107c60841a233</citedby><cites>FETCH-LOGICAL-c389t-14869880254f555eba68d27793caadb8057aef2b8604ee38ca59107c60841a233</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=28740125$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24995685$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tian, Li</creatorcontrib><creatorcontrib>Tan, Yunlong</creatorcontrib><creatorcontrib>Chen, Dachun</creatorcontrib><creatorcontrib>Lv, Menghan</creatorcontrib><creatorcontrib>Tan, Shuping</creatorcontrib><creatorcontrib>Soares, Jair C.</creatorcontrib><creatorcontrib>Zhang, Xiang Yang</creatorcontrib><title>Reduced serum TNF alpha level in chronic schizophrenia patients with or without tardive dyskinesia</title><title>Progress in neuro-psychopharmacology & biological psychiatry</title><addtitle>Prog Neuropsychopharmacol Biol Psychiatry</addtitle><description>Mounting evidences have demonstrated the association of altered immune factors with neurodevelopmental and pathological progression of schizophrenia. However, whether immune factors play any role in the pathogenesis of tardive dyskinesia (TD) has been underexplored. To our best knowledge, ours is among the piloting studies examining the association of TNF alpha with extrapyramidal symptoms of schizophrenic patients so far.
The aim of this study was to assess the clinical significance of serum TNF alpha level in chronic schizophrenia, especially its potential association with TD.
Serum TNF alpha level was measured in a sandwich enzyme-linked immunosorbent assay (ELISA) from 46 medicated chronic schizophrenia patients with TD, 43 chronic schizophrenia patients without TD, and 43 healthy control subjects. The symptoms of schizophrenia were assessed by the positive and negative syndrome scale (PANSS).
Chronic patients both with TD and without TD had significantly lower serum level of TNF alpha than controls (TD=9.5±2.1pg/ml, non-TD=10.7±1.8pg/ml, control=37.8±3.4pg/ml, p<0.001). Compared to patients without TD, TD patients showed marginally significant reduction in the serum TNF alpha level (p=0.05). The reduced TNF alpha level was not significantly affected by daily dose or duration of antipsychotic drugs (p>0.05). Serum TNF alpha level was negatively correlated with the PANSS total score in the whole schizophrenia patients (p<0.01), but no significant association with TD severity was observed.
Our results suggested that at chronic stage, serum TNF activity is associated with psychopathology of schizophrenia patients, but whether it can be a biomarker for TD needs further clarification in the future.
•Chronic schizophrenia patients had lower TNFα level than healthy controls.•A marginally significant decrease in TNFα was noted in TD than non-TD patients.•TNFα was correlated with psychopathology of schizophrenia, but not TD severity.</description><subject>Adult and adolescent clinical studies</subject><subject>Antipsychotic Agents - therapeutic use</subject><subject>Antipsychotics</subject><subject>Biological and medical sciences</subject><subject>Chronic Disease</subject><subject>Cross-Sectional Studies</subject><subject>Enzyme-Linked Immunosorbent Assay</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Movement Disorders - complications</subject><subject>Movement Disorders - immunology</subject><subject>Nervous system (semeiology, syndromes)</subject><subject>Nervous system as a whole</subject><subject>Neurology</subject><subject>Neuropharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Psychiatric Status Rating Scales</subject><subject>Psycholeptics: tranquillizer, neuroleptic</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology</subject><subject>Psychopathology. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Psychoses</subject><subject>Schizophrenia</subject><subject>Schizophrenia - complications</subject><subject>Schizophrenia - drug therapy</subject><subject>Schizophrenia - immunology</subject><subject>Severity of Illness Index</subject><subject>Tardive dyskinesia</subject><subject>Tumor necrosis factor</subject><subject>Tumor Necrosis Factor-alpha - blood</subject><issn>0278-5846</issn><issn>1878-4216</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><recordid>eNp9kcFu1DAQhi0EokvhCZCQL0hcNowd23EOHFDVAlIFEipna-JMFC_ZJNjJovL0eLsL3DjNHL75Z_QNYy8FFAKEebsr5nFu5kKCUAWYAoR8xDbCVnarpDCP2QZk7rVV5oI9S2kHAKKE8im7kKqutbF6w5qv1K6eWp4ornt-9_mG4zD3yAc60MDDyH0fpzF4nnwffk1zH2kMyGdcAo1L4j_D0vMpPtRpXfiCsQ0H4u19-h5GSgGfsycdDolenOsl-3ZzfXf1cXv75cOnq_e3W1_aetkKZU1tLUitOq01NWhsK6uqLj1i21jQFVInG2tAEZXWo64FVN6AVQJlWV6yN6fcOU4_VkqL24fkaRhwpGlNTmitVJUF6IyWJ9THKaVInZtj2GO8dwLcUa7buQe57ijXgXFZbp56dV6wNntq_878sZmB12cAk8ehizj6kP5xtlI558i9O3GUdRwCRZd8tpnfECL5xbVT-O8hvwFrwZk7</recordid><startdate>20141003</startdate><enddate>20141003</enddate><creator>Tian, Li</creator><creator>Tan, Yunlong</creator><creator>Chen, Dachun</creator><creator>Lv, Menghan</creator><creator>Tan, Shuping</creator><creator>Soares, Jair C.</creator><creator>Zhang, Xiang Yang</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20141003</creationdate><title>Reduced serum TNF alpha level in chronic schizophrenia patients with or without tardive dyskinesia</title><author>Tian, Li ; Tan, Yunlong ; Chen, Dachun ; Lv, Menghan ; Tan, Shuping ; Soares, Jair C. ; Zhang, Xiang Yang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c389t-14869880254f555eba68d27793caadb8057aef2b8604ee38ca59107c60841a233</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adult and adolescent clinical studies</topic><topic>Antipsychotic Agents - therapeutic use</topic><topic>Antipsychotics</topic><topic>Biological and medical sciences</topic><topic>Chronic Disease</topic><topic>Cross-Sectional Studies</topic><topic>Enzyme-Linked Immunosorbent Assay</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Movement Disorders - complications</topic><topic>Movement Disorders - immunology</topic><topic>Nervous system (semeiology, syndromes)</topic><topic>Nervous system as a whole</topic><topic>Neurology</topic><topic>Neuropharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Psychiatric Status Rating Scales</topic><topic>Psycholeptics: tranquillizer, neuroleptic</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology</topic><topic>Psychopathology. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Psychoses</topic><topic>Schizophrenia</topic><topic>Schizophrenia - complications</topic><topic>Schizophrenia - drug therapy</topic><topic>Schizophrenia - immunology</topic><topic>Severity of Illness Index</topic><topic>Tardive dyskinesia</topic><topic>Tumor necrosis factor</topic><topic>Tumor Necrosis Factor-alpha - blood</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tian, Li</creatorcontrib><creatorcontrib>Tan, Yunlong</creatorcontrib><creatorcontrib>Chen, Dachun</creatorcontrib><creatorcontrib>Lv, Menghan</creatorcontrib><creatorcontrib>Tan, Shuping</creatorcontrib><creatorcontrib>Soares, Jair C.</creatorcontrib><creatorcontrib>Zhang, Xiang Yang</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Progress in neuro-psychopharmacology & biological psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tian, Li</au><au>Tan, Yunlong</au><au>Chen, Dachun</au><au>Lv, Menghan</au><au>Tan, Shuping</au><au>Soares, Jair C.</au><au>Zhang, Xiang Yang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Reduced serum TNF alpha level in chronic schizophrenia patients with or without tardive dyskinesia</atitle><jtitle>Progress in neuro-psychopharmacology & biological psychiatry</jtitle><addtitle>Prog Neuropsychopharmacol Biol Psychiatry</addtitle><date>2014-10-03</date><risdate>2014</risdate><volume>54</volume><spage>259</spage><epage>264</epage><pages>259-264</pages><issn>0278-5846</issn><eissn>1878-4216</eissn><coden>PNPPD7</coden><abstract>Mounting evidences have demonstrated the association of altered immune factors with neurodevelopmental and pathological progression of schizophrenia. However, whether immune factors play any role in the pathogenesis of tardive dyskinesia (TD) has been underexplored. To our best knowledge, ours is among the piloting studies examining the association of TNF alpha with extrapyramidal symptoms of schizophrenic patients so far.
The aim of this study was to assess the clinical significance of serum TNF alpha level in chronic schizophrenia, especially its potential association with TD.
Serum TNF alpha level was measured in a sandwich enzyme-linked immunosorbent assay (ELISA) from 46 medicated chronic schizophrenia patients with TD, 43 chronic schizophrenia patients without TD, and 43 healthy control subjects. The symptoms of schizophrenia were assessed by the positive and negative syndrome scale (PANSS).
Chronic patients both with TD and without TD had significantly lower serum level of TNF alpha than controls (TD=9.5±2.1pg/ml, non-TD=10.7±1.8pg/ml, control=37.8±3.4pg/ml, p<0.001). Compared to patients without TD, TD patients showed marginally significant reduction in the serum TNF alpha level (p=0.05). The reduced TNF alpha level was not significantly affected by daily dose or duration of antipsychotic drugs (p>0.05). Serum TNF alpha level was negatively correlated with the PANSS total score in the whole schizophrenia patients (p<0.01), but no significant association with TD severity was observed.
Our results suggested that at chronic stage, serum TNF activity is associated with psychopathology of schizophrenia patients, but whether it can be a biomarker for TD needs further clarification in the future.
•Chronic schizophrenia patients had lower TNFα level than healthy controls.•A marginally significant decrease in TNFα was noted in TD than non-TD patients.•TNFα was correlated with psychopathology of schizophrenia, but not TD severity.</abstract><cop>Amsterdam</cop><pub>Elsevier Inc</pub><pmid>24995685</pmid><doi>10.1016/j.pnpbp.2014.06.012</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0278-5846 |
| ispartof | Progress in neuro-psychopharmacology & biological psychiatry, 2014-10, Vol.54, p.259-264 |
| issn | 0278-5846 1878-4216 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1554473035 |
| source | ScienceDirect Journals |
| subjects | Adult and adolescent clinical studies Antipsychotic Agents - therapeutic use Antipsychotics Biological and medical sciences Chronic Disease Cross-Sectional Studies Enzyme-Linked Immunosorbent Assay Female Humans Male Medical sciences Middle Aged Movement Disorders - complications Movement Disorders - immunology Nervous system (semeiology, syndromes) Nervous system as a whole Neurology Neuropharmacology Pharmacology. Drug treatments Psychiatric Status Rating Scales Psycholeptics: tranquillizer, neuroleptic Psychology. Psychoanalysis. Psychiatry Psychopathology Psychopathology. Psychiatry Psychopharmacology Psychoses Schizophrenia Schizophrenia - complications Schizophrenia - drug therapy Schizophrenia - immunology Severity of Illness Index Tardive dyskinesia Tumor necrosis factor Tumor Necrosis Factor-alpha - blood |
| title | Reduced serum TNF alpha level in chronic schizophrenia patients with or without tardive dyskinesia |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T08%3A26%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Reduced%20serum%20TNF%20alpha%20level%20in%20chronic%20schizophrenia%20patients%20with%20or%20without%20tardive%20dyskinesia&rft.jtitle=Progress%20in%20neuro-psychopharmacology%20&%20biological%20psychiatry&rft.au=Tian,%20Li&rft.date=2014-10-03&rft.volume=54&rft.spage=259&rft.epage=264&rft.pages=259-264&rft.issn=0278-5846&rft.eissn=1878-4216&rft.coden=PNPPD7&rft_id=info:doi/10.1016/j.pnpbp.2014.06.012&rft_dat=%3Cproquest_cross%3E1554473035%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c389t-14869880254f555eba68d27793caadb8057aef2b8604ee38ca59107c60841a233%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1554473035&rft_id=info:pmid/24995685&rfr_iscdi=true |